Home » Posts tagged 'shareholders' (Page 2)
Tag Archives: shareholders
#KAV Kavango Resources PLC – Notice of General Meeting
Kavango Resources plc (LSE:KAV), the Southern Africa-focused metals exploration company, is pleased to announce that it will today post a copy of a notice of general meeting (the “General Meeting Notice” or “Circular”) and form of proxy for the general meeting to shareholders. The general meeting is to be held at 11 a.m. on 25 October 2023 at the offices of the Company’s Solicitors, Druces LLP, Salisbury House, London Wall, London EC2M 5PS (the “General Meeting”). The Company will also make these documents available to download from the Company’s website (www.kavangoresources.com).
In accordance with Listing Rule 14.3.6 of the UK Financial Conduct Authority (“FCA”), a copy of the General Meeting Notice will be submitted to the FCA via the National Storage Mechanism and will shortly be available to the public for inspection at:
https://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism
Background
The General Meeting Notice will be published and posted to shareholders today, together with a form of proxy, providing notification of the General Meeting to consider the resolutions set out below.
Resolutions have been tabled to (i) seek approval from independent shareholders of a waiver in accordance with Rule 9 of the Takeover Code (Whitewash) in relation to the Stage 2 Subscription (as announced on 09 May 2023), (ii) issue and allot, or grant rights to subscribe for or convert any securities into the Stage 2 Subscription Shares, and to (iii) allot equity securities (as defined in section 560(1) of the Companies Act 2006) for cash in respect of the Stage 2 Subscription Shares on a non-premptive basis.
Further information in respect of Kavango and its business interests is provided on the Company’s website at www.kavangoresources.com and on X (formerly known as Twitter) at #KAV.
For further information please contact:
Kavango Resources plc
Ben Turney
+46 7697 406 06
First Equity (Broker)
+44 207 374 2212
Jason Robertson
Golden Metal Resources #GMET – Total Voting Rights
In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, the Company hereby announces that as at 30 June 2023 there were 85,000,255 ordinary shares of 1 pence each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 85,000,255.
The above figure of 85,000,255 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
For further information visit www.goldenmetalresources.com or contact the following:
|
Golden Metal Resources plc Oliver Friesen (CEO) |
Tel: +44 (0) 20 7583 8304 |
|
Cairn Financial Advisers LLP Nominated Adviser Sandy Jamieson/Jo Turner/Louise O’Driscoll |
Tel: +44 20 7213 0880 |
|
First Equity Limited Broker Jonathan Brown/Jason Robertson |
Tel: +44 20 7374 2212 |
The Projects:
Pilot Mountain Project
The Pilot Mountain project is an advanced exploration and mineral resource definition stage project located in Mineral County in western Nevada. The project covers an area of 14.80 km2 (3,656.1 acres) and is located 200km southeast of Reno and 18km east of Mina, Nevada. It is well situated for the supply of power, water and skilled labour and proximity to transport infrastructure in Mineral County and is centred around four existing mineral deposits: Garnet; Good Hope; Gunmetal and Desert Scheelite, all of which possess significant skarn-style tungsten-copper-silver-zinc mineralisation. The Pilot Mountain project consists of 176 active lode mining claims and 4 filed mill site claims. The four mill site claims filed at the former Dunham mill site have secure access to groundwater supply sufficient for the proposed project.
Golconda Summit Project
Golden Metal is the operator of the Golconda Summit project, which is held under an earn-in right to acquire up to 100 per cent. of the project from the mineral claim owner pursuant to an option agreement. The Golconda Summit project is an exploration stage gold and silver project located in Humboldt County and situated at the confluence of the Getchell and Battle Mountain – Eureka metallogenic trends, and consists of 44 lode mining claims, covering a total area of approximately 3.22 km2 (795.4 acres) located approximately 27km east of Winnemucca.
Garfield Project
The Garfield project is an early exploration stage copper, gold and silver property consisting of 39 lode mining claims covering 3.23 km2 (797.9 acres) located in Mineral County, Nevada, approximately 14km due east of the town of Hawthorne and 120km due west-northwest of Tonopah.
Stonewall Project
The Stonewall project is an exploration stage gold-silver property prospective for epithermal gold-silver mineralisation. The property consists of 19 lode mining claims covering 1.59 km2 (392.5 acres) located on the northern flank of Stonewall Mountain, on the western edge of the Nellis Airforce Range Restricted Access Area, in Nye County, Nevada, approximately 24km south-east of the historic gold mining town of Goldfield and 60km due south of Tonopah.
Power Metal Resources #POW – Major Shareholding
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: |
Power Metal Resources plc |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
||||||
|
Non-UK issuer |
||||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
||||||
|
An event changing the breakdown of voting rights |
||||||
|
Other (please specify)iii: |
||||||
|
3. Details of person subject to the notification obligationiv |
||||||
|
Name |
Mohamed Zafar Quraishi |
|||||
|
City and country of registered office (if applicable) |
||||||
|
4. Full name of shareholder(s) (if different from 3.)v |
||||||
|
Name |
||||||
|
City and country of registered office (if applicable) |
||||||
|
5. Date on which the threshold was crossed or reachedvi: |
22/03/23 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
22/03/23 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuervii |
|||
|
Resulting situation on the date on which threshold was crossed or reached |
3.03% |
3.03% |
1,739,033,678 |
|||
|
Position of previous notification (if applicable) |
||||||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
|||||||||
|
A: Voting rights attached to shares |
|||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rightsix |
% of voting rights |
|||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
|
GB00BYWJZ743 Ordinary Shares
|
52,674,950 |
3.03% |
|||||||
|
SUBTOTAL 8. A |
|||||||||
|
|
|||||||||
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|||||
|
SUBTOTAL 8. B 1 |
|||||||||
|
|
|||||||||
|
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlementxii |
Number of voting rights |
% of voting rights |
||||
|
|
SUBTOTAL 8.B.2 |
||||||||
|
|
|||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
X |
|||
|
Full chain of controlled undertakings through which the voting rights and/or the |
||||
|
Namexv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
|
||||
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
||||
|
The number and % of voting rights held |
||||
|
The date until which the voting rights will be held |
||||
|
11. Additional informationxvi |
||||
|
Place of completion |
Hayes, UK |
|
Date of completion |
22/03/2023 |
#ORPH Open Orphan – Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee.
Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding a number of senior roles at healthcare AI businesses. Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships.
Martin is currently Global SVP, Business Development at Owkin, a French-American start-up using artificial intelligence to discover and develop better treatments for unmet medical needs. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare, an international M&A advisory firm, where he co-led the company’s healthcare practice. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.
Martin holds a BSc in Genetics and has completed a range of post graduate management courses.
Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: “I am pleased to welcome Martin to the Board of Open Orphan. Martin has extensive corporate development experience in the CRO, healthcare and pharmaceutical sectors and held a number of senior roles in healthcare AI businesses. I look forward to working closely with Martin as we drive further growth across the business.”
Martin Gouldstone, Non-Executive Director, said: “I am delighted to join the Board of Open Orphan at what is an exciting time for the Company and the infectious disease market as it continues to grow significantly post pandemic. I am delighted to bring my previous three decades of experience in the CRO, healthcare and pharmaceutical industry to the Company as it continues to build and expand on partnerships with leading global biopharma companies.”
Regulatory Disclosures
Save for the information set out above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule Two (g) of the AIM Rules for Companies in respect of the appointment of Mr Martin John Gouldstone, aged 55, Martin does not hold an interest in the Company’s share capital.
|
Current Directorships |
Past Directorships |
|
Novara Therapeutics Limited |
n.a. |
|
Orthopaedic Research UK |
|
|
Sempiternum Ltd |
|
For further information please contact:
|
Open Orphan plc |
+44 20 7756 1300 |
||
|
Yamin ‘Mo’ Khan, Chief Executive Officer |
|||
|
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
|
Ben Cryer / Edward Mansfield / Phil Walker / Will King |
|||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / James Thompson / Richard Chambers |
|||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell |
|||
|
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / |
||
UK Investor Magazine podcast with Alan Green covering Aston Martin #AML, JD Wetherspoons #JDW and Vast Resources #VAST
UK Investor Magazine podcast with Alan Green covering Aston Martin #AML, JD Wetherspoons #JDW and Vast Resources #VAST
Aston Martin, Wetherspoons, and Vast Resources with Alan Green
Alan Green joins the UK Investor Magazine Podcast for a broad discussion around UK equities and key market themes.
We look at FTSE 100 outperformance vs US peers and how commodities shares have supported London’s leading index during a period of sharp declines in US tech stocks
Aston Martin have soared on a positive update and we look the merits of AML shares trading just below 1,000p.
Wetherspoons could offer opportunity during times of economic downturn and with shares way of 52-week highs and steady sales, the stock may be worth a look.
Vast Resources has produced a remarkable gain over the past week and we breakdown the reason for the move, and if it has further to go
#ORPH Open Orphan – Appointment of Nominated Adviser and Joint Broker
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to the announcements by Arden Partners Plc on 11 and 14 April 2022 regarding the loss of its Nominated Adviser status upon the completion of its recommended takeover, the Company has appointed Liberum Capital Limited (“Liberum”) as its Nominated Adviser and Joint Broker. Given the timing of the completion of the recommended takeover of Arden Partners Plc, the Exchange has agreed that subject to initial due diligence being undertaken, Liberum has until 5pm on 27 July 2022 to complete its full due diligence.
There can be no guarantee on the outcome of the full due diligence and its impact on Liberum’s decision to continue to act as Nominated Adviser. Accordingly, in such circumstances there is a risk that if the Liberum does not continue to act as Nominated Adviser following completion of its full due diligence and the Company has not found an alternative Nominated Adviser, the Company’s AIM securities may be suspended pursuant to AIM Rule 1. If within one month of that suspension, the Company has failed to appoint a replacement Nominated Adviser, the admission of its AIM securities will be cancelled.
Notwithstanding the extension of time provided in respect of completing full due diligence obligations at engagement, Liberum will continue to be subject to all the ongoing Nominated Adviser responsibilities under the AIM Rules for Nominated Advisers.
finnCap plc and Davy will continue to act as the Company’s Joint Brokers.
Yamin ‘Mo’ Khan, Chief Executive Officer at Open Orphan, said: “As the market is aware, Arden Partners can no longer act as Nomad for listed companies from 29 April 2022 and as such, we thank them for their support over the past number of years. We are delighted to now be working with such a prestigious investment bank as Liberum.”
For further information please contact:
|
Open Orphan plc |
+353 (0) 1 644 0007 |
||
|
Cathal Friel, Executive Chairman Yamin Khan, Chief Executive Officer |
|
||
|
|
|
||
|
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
|
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King |
|
||
|
|
|
||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / James Thompson / Richard Chambers |
|
||
|
|
|
||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell |
|
||
|
|
|
||
|
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |
||
#ECR ECR Minerals – Warrant Exercise
Resolutions of the Board of Directors of the Company (the “Board”)
22nd April 2022
WHEREAS the Board received notice to exercise warrants over 20,500,000 new ordinary shares in the Company at an exercise price of 1p per share (“Warrant Shares”). Subscription monies of £205,000.00 have been received by ECR in respect of the exercise of these warrants and a copy of the warrant certificate was received by ECR from the Warrant Holder for the exercise of these warrants.
IT WAS RESOLVED:
- that the issue and allotment of a total of 20,500,000 ordinary shares of ECR Minerals Plc of £0.00001 be authorised in connection with the above, application be made for the admission of the shares to trading on AIM, the Company’s registrars be authorised to take all steps necessary to effect the issue and allotment of the shares, and the appropriate regulatory announcement be made;
- that copies of this resolution (or extracts thereof, as appropriate) be supplied to the Company’s AIM nominated adviser and the Company’s registrars as necessary, and that the Company Secretary be instructed to make all necessary filings with Companies House in connection with the issue and allotment of the shares.
SIGNED
David Tang
Chairman
FOR FURTHER INFORMATION, PLEASE CONTACT:
|
ECR Minerals plc |
|
Tel: +44 (0) 20 7929 1010 |
|
|
|
David Tang, Non-Executive Chairman Andrew Haythorpe, CEO |
|
|
|
|
|
|
|
|
|
|
|
Email: |
|
|
|
|
|
Website: www.ecrminerals.com |
|
|
|
|
|
|
|
|
|
|
|
WH Ireland Ltd |
|
Tel: +44 (0) 207 220 1666 |
|
|
|
Nominated Adviser Katy Mitchell / Andrew de Andrade |
|
|
|
|
|
|
|
|
|
|
|
SI Capital Ltd |
|
Tel: +44 (0) 1483 413500 |
|
|
|
Broker |
|
|
|
|
|
Nick Emerson |
|
|
|
|
|
|
|
|
|
|
|
Novum Securities Limited |
|
Tel: +44 (0) 20 7399 9425 |
|
|
|
Broker Jon Belliss |
|
|
|
|
|
|
|
|
|
|
|
Blytheweigh |
|
Tel: +44 (0) 207 138 3204 |
|
|
|
Public Relations |
|
|
|
|
|
Tim Blythe
|
||||
#TM1 Technology Minerals – Recyclus appoints Group Managing Director
Technology Minerals Plc (LSE: TM1), the first listed UK company focused on creating a sustainable circular economy for battery metals, is pleased to announce that its 49% owned battery recycling business, Recyclus Group Ltd (“Recyclus”), has appointed Matthew Taylor as Group Managing Director.
Matthew has over 40 years’ experience working in senior management roles, across a number of key industrial and manufacturing sectors in the UK, including avionics, automotive, consumer and professional power tools, power generation engineering, marine and aero engineering. He was formally General Manager at a leading UK-based specialist aerospace metals group to the international aerospace sector, where under his leadership, revenues underwent an increase of 40 per cent and gross margins were improved by 100 per cent.
He was principal consultant at Smith Kenyon Ltd, a leading business transformation specialist, for 18 years working successfully on transformation projects with leading industrial companies in the UK and internationally. Projects included operations and supply chain management, strategic evaluations, specialist procurement evaluations and strategies, business development and design and implementation of manufacturing operations.
Former roles also include a main board member at Cummins Power Generation with the brief to transform supply chain, operations and global purchasing, with plants in UK, China, India, Mexico, Singapore, USA, Germany and Romania. With global sales and distribution, Cummins Power Generation is a global manufacturer, distributor and brand leader in the international power generation engineering sector with a $2bn turnover and a division of Cummins Inc. with $6bn annualised turnover.
Matthew holds a BSc Management, Engineering, Production and Economics, MBA and is a PRINCE2 practitioner and 6 Sigma trained.
Matthew Taylor, Group Managing Director of Recyclus, said : “It’s great to formally join the team at Recyclus at such a formative stage in the company’s evolution and particularly as we enter the first growth stage of the business. The team are well versed in how the proprietary technology at play here can form such an important role in the UK battery ecosystem as we take on the lead role in the industrial scale-up in lithium-ion battery recycling. I look forward to joining the team and driving the development of solutions for battery testing and take-back recycling, with a clear focus on surpassing our customer’s needs and requirements.”
Robin Brundle, Chairman of Technology Minerals and Director of Recyclus, said : “Matthew is well-practised in building transformational businesses in key industrial sectors and his appointment comes at a very appropriate stage for Recyclus Group. He comes to us with a very strong track record in successfully achieving his commercial goals, and his sector experience mirrors that of the main industrial sectors for Recyclus.”
Enquiries
|
Technology Minerals Plc |
|
|
Robin Brundle, Executive Chairman Alexander Stanbury, Chief Executive Officer |
+44 20 7618 9100 |
|
Arden Partners Plc |
|
|
Ruari McGirr, George Morgan |
+44 207 614 5900 |
|
Luther Pendragon |
|
|
Harry Chathli, Alexis Gore, John Bick |
+44 20 7618 9100 |
#ORPH Open Orphan – Launch of STRiVE project
Respiratory viral strains suitable for challenge agents being collected from consenting volunteers
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has recently launched the STRiVE project (Seasonal Transmissible Respiratory Virus SurvEy) to collect respiratory viral strains suitable for challenge agents from consenting hVIVO employees. Collection of new respiratory viral strains circulating in the community will allow hVIVO to continually update and broaden its world leading portfolio of human challenge study models.
As part of STRiVE, volunteers with cold or flu like symptoms can send nasal swabs to hVIVO for analysis. Since starting the project, hVIVO has identified over 180 promising virus candidates that could be used in the manufacture of novel challenge agents for its human challenge trials. Viruses isolated include several strains of coronavirus, adenovirus, human metapneumovirus (HMPV), human rhinovirus (HRV), parainfluenza virus (PIV), influenza, and respiratory syncytial virus (RSV).
STRiVE ensures hVIVO can regularly update its challenge agent portfolio with relevant strains as viruses mutate over time. Manufacturing antigenically relevant strains on demand broadens hVIVO’s repository of viral pathogens and could help extend the range of human challenge models it currently offers.
The average UK adult has an estimated 2-4 respiratory infections each year, resulting in billions of pounds of lost output due to illness. Despite familiarity with the negative impacts of cold and flu viruses, remarkably little is understood about the hundreds of viruses responsible that cause illness, including transmission and markers of protective immunity. Using human challenge modelling to better understand such issues could enable future public health benefits and savings.
hVIVO has two decades of experience and expertise in safely conducting challenge studies across a range of respiratory and infectious diseases, including various strains of influenza, RSV, human rhinovirus (HRV – common cold virus), malaria, and asthma. This portfolio has also expanded to include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan, said: “Despite only commencing recently, STRIVE has already been a remarkable success, with over 180 viruses identified and 12 different strains, with potential to be used as challenge agents in hVIVO human challenge trials. I would like to thank all hVIVO employees who have thus far participated and encourage more to do so in order to continue to build up this important repository for cold and flu research.
“Importantly, the STRIVE clinical research project will play a significant role in the Company’s efforts to broaden its world leading portfolio of human challenge models.”
Adrian Wildfire, Director of Scientific and Business Strategy at hVIVO, commented: “Access to viable strains of circulating respiratory pathogens is extremely limited and this often presents a significant obstacle to anyone seeking to grow a new viral challenge agent. To grow a new viral strain a virus must be collected from a human host, processed and stored in an adequate manner to keep the virus alive.
“STRIVE will allow the Company to use its expertise to monitor the viral strains of cold and flu that are circulating in the community, and potentially lead to the discovery of new, wild type challenge agents and the development of new human challenge models with unparalleled translation into the field.”
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.
Individuals interested in taking part in COVID-19 human challenge study research can learn more at www.UKCovidChallenge.com.
For further information please contact:
| Open Orphan plc | +353 (0) 1 644 0007 | |||
| Cathal Friel, Executive Chairman | ||||
| Arden Partners plc (Nominated Adviser and Joint Broker) | +44 (0) 20 7614 5900 | |||
| John Llewellyn-Lloyd / Louisa Waddell | ||||
| finnCap plc (Joint Broker) | +44 (0) 20 7220 0500 | |||
| Geoff Nash / James Thompson / Richard Chambers | ||||
| Davy (Euronext Growth Adviser and Joint Broker) | +353 (0) 1 679 6363 | |||
| Anthony Farrell | ||||
| Walbrook PR (Financial PR & IR) | +44 (0)20 7933 8780 or openorphan@walbrookpr.com | |||
| Paul McManus/ Sam Allen / Louis Ashe-Jepson | +44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 | |||